11 Dec 2025
byProf. Natalia Valdiviezo, San Ignacio de Loyola University, Lima, Peru; Dr. Herbert Loong, Department of Clinical Oncology, Chinese University of Hong Kong; Dr. James Ho; Dr. Michael Kam, Specialist in Clinical Oncology, Hong Kong
The treatment landscape for EGFR-mutated (EGFRm) non-small-cell lung cancer (NSCLC) is rapidly evolving, with many exciting developments on the horizon. At a recent scientific symposium, experts in lung cancer gathered to review the latest advances. This article highlights the key takeaways from the symposium, summarizing FLAURA2 trial data presented by Professor Natalia Valdiviezo from San Ignacio de Loyola University, Lima, Peru, and main insights from the panel discussion led by Dr Herbert Loong from the Department of Clinical Oncology, the Chinese University of Hong Kong, with contributions from Dr James Ho of the Department of Medicine, University of Hong Kong, and Dr Michael Kam, Specialist in Clinical Oncology in Hong Kong.